AVXL · Anavex Life Sciences Corp. · Documents
$1.29
-0.07 (-5.15%)
At close · Oct 23
Return incl. dividend (before tax)
Market Cap
$120.97M
Shares
92.70M
Volume · Oct 23
626.22K
Avg daily vol (3M)
1.03M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | Anavex Life Sciences Corp. announced on October 15, 2026 that the FDA cleared its IND for blarcamesine in Fragile X syndrome, enabling a planned Phase 2a trial in approximately 60 adult males. Blarcamesine previously received FDA Orphan Drug Designation for Fragile X syndrome. | 2026-10-15 | — | |
| 8-K | — | 2026-09-28 | 2026-09-24 | |
| DEFA14A | — | 2026-09-15 | — | |
| DEFA14A | — | 2026-09-14 | — | |
| 8-K | — | 2026-09-09 | — | |
| DEFA14A | — | 2026-09-08 | — | |
| DEFA14A | — | 2026-09-04 | — | |
| 8-K | — | 2026-09-02 | — | |
| DEFA14A | — | 2026-09-01 | — | |
| DEFA14A | — | 2026-08-31 | — | |
| 10-Q | — | 2026-08-28 | 2026-06-30 | |
| 10-Q/A | — | 2026-08-28 | 2025-12-31 | |
| 10-K/A | — | 2026-08-28 | 2025-09-30 | |
| 10-Q | — | 2026-08-28 | 2026-03-31 | |
| 8-K | — | 2026-08-25 | — | |
| DEFA14A | — | 2026-08-24 | — | |
| DEFA14A | — | 2026-08-17 | — | |
| 8-K | — | 2026-08-17 | — | |
| DEFA14A | — | 2026-08-17 | — | |
| DEFA14A | — | 2026-08-11 | — | |
| 8-K | — | 2026-08-11 | — | |
| NT 10-Q | — | 2026-08-10 | 2026-06-30 | |
| 8-K | — | 2026-08-03 | — | |
| 8-K | — | 2026-07-30 | — | |
| 8-K | — | 2026-07-20 | — | |
| 8-K | — | 2026-06-26 | 2026-06-25 | |
| 8-K | — | 2026-05-22 | 2026-05-20 | |
| 8-K | — | 2026-05-15 | 2026-05-11 | |
| NT 10-Q | — | 2026-05-11 | 2026-03-31 | |
| 8-K | — | 2026-05-06 | 2026-04-30 | |
| 8-K | — | 2026-03-25 | — | |
| 8-K | — | 2026-02-25 | 2026-02-20 | |
| 10-Q | — | 2026-02-09 | 2025-12-31 | |
| 8-K | — | 2026-02-09 | — | |
| 8-K | — | 2025-11-25 | — | |
| 10-K | — | 2025-11-25 | 2025-09-30 | |
| 8-K | — | 2025-11-14 | — | |
| 10-Q | — | 2025-08-12 | 2025-06-30 | |
| 8-K | — | 2025-07-28 | 2025-07-25 | |
| S-3 | — | 2025-07-14 | — | |
| 8-K | — | 2025-07-03 | — | |
| 8-K | — | 2025-06-13 | 2025-06-10 | |
| 10-Q | — | 2025-05-13 | 2025-03-31 | |
| DEFA14A | — | 2025-04-25 | — | |
| ARS | — | 2025-04-25 | 2024-09-30 | |
| DEF 14A | — | 2025-04-25 | — | |
| 10-Q | — | 2025-02-12 | 2024-12-31 | |
| 10-K | — | 2024-12-23 | 2024-09-30 | |
| 10-Q | — | 2024-08-06 | 2024-06-30 | |
| 8-K | — | 2024-07-30 | 2024-07-24 |
Showing 1–50 of 104 filings
Key facts
CIK
1314052
CUSIP
032797300
13F (30d)
25 filings
25 filers
Visit website
Investor relations